Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAnthem Kimmtrak Prior Auth Coverage Update | OpenP…
    Ask Trek AI about this page
    CurrentAnthemPolicy CC-0211

    Kimmtrak (tebentafusp-tebn)

    Customize your policy alerts

    Sign up for Anthem Policy CC-0211 alerts

    Get alerted when Policy CC-0211 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical criteria governing prior authorization and medical necessity determinations for Kimmtrak (tebentafusp-tebn) for treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma under the medical benefit.

    Policy Summary
    PayerAnthem
    PolicyKimmtrak (tebentafusp-tebn)
    Policy CodePolicy CC-0211
    Change TypeNo material changes
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review DateFeb 20, 2026
    Key ActionObtain prior authorization and document HLA-A*02:01 positivity, diagnosis of unresectable or metastatic uveal melanoma, and ECOG 0-1.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Unresectable or metastatic uveal melanomaindication covered
    HLA-A*02:01required genotype
    ECOG 0-1

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    performance status
    J9274HCPCS

    Coverage Criteria

    Approval criteria

    Requests for Kimmtrak (tebentafusp-tebn) may be approved if the following criteria are met:

    Age exception: Individual is under 19 years of age

    Listed as an approval pathway

    Standard adult criteria: Individual has a diagnosis of unresectable or metastatic uveal melanoma AND is HLA-A*02:01 positive AND has ECOG performance status 0-1

    Matches FDA label and NCCN 1

    Requests may not be approved when the criteria above are not met and for all other indications.

    Initial Therapy Criteria

    Initial therapy criteria

    Initial approval criteria

    Pediatric pathway: Individual is under 19 years of age

    Pediatric approval listed

    Adult pathway: Diagnosis of unresectable or metastatic uveal melanoma AND HLA-A*02:01 positive genotype AND ECOG performance status 0-1

    Per label and NCCN

    Coding

    HCPCSHCPCSCovered
    J9274Injection, tebentafusp-tebn, 1 microgram [Kimmtrak]
    ICD-10 DiagnosisICD-10
    C69.30-C69.32Malignant neoplasm of choroid
    C69.40-C69.42Malignant neoplasm of ciliary body
    C69.60-C69.62Malignant neoplasm of orbit
    inv-05: ECOG performance status — 0-1
    ECOG performance status requirement0-1
    PurposeUsed as an eligibility threshold for Kimmtrak (tebentafusp-tebn) prior authorization decisions
    Source contextListed as part of the standard adult approval criteria for unresectable or metastatic uveal melanoma

    Provider Actions & Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Kimmtrak (tebentafusp-tebn). Requests will be considered only when the clinical criteria in the policy are met (age, diagnosis of unresectable or metastatic uveal melanoma, HLA-A*02:01 positive genotype, and ECOG performance status 0-1).

    • Policy number: CC-0211
    • Drug: Kimmtrak (tebentafusp-tebn)
    Step Therapy

    Step Therapy

    No step therapy or prior conventional therapy is required for Kimmtrak under this policy.

    Documentation Required

    Site of Care

    Note

    No site-of-care restrictions specified

    The policy does not impose any specific site-of-care or infusion center restrictions for administration of Kimmtrak.

    Step Therapy

    StepRequirement
    {"text":"1","status":""},{"text":"No step therapy requirements or prior conventional therapy requirements are specified in this policy.","status":""}

    Background

    Kimmtrak (tebentafusp-tebn) is a bispecific gp100 peptide–HLA-directed CD3 T cell engager indicated for treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma. The agent carries a boxed warning for cytokine release syndrome, which can be serious or life‑threatening; clinicians and infusion centers should be prepared to monitor and manage CRS per established protocols. Prior authorization is required and approval is contingent on meeting the policy’s clinical criteria (diagnosis of unresectable or metastatic uveal melanoma, documented HLA‑A*02:01 positivity, and ECOG performance status 0-1), with a pediatric approval pathway for individuals under 19 years of age noted separately.

    Definitions

    inv-11: Melanoma — definition
    DefinitionA type of cancer that begins in the melanocytes; also referred to as malignant melanoma and cutaneous melanoma.
    Typical originArises from melanocytes, the pigment-producing cells of the skin (and less commonly other sites).
    Relevance to policyPolicy applies to uveal melanoma (a melanoma subtype) when unresectable or metastatic and HLA-A*02:01 positive.
    inv-12: Metastasis — definition
    DefinitionThe spread of cancer from one part of the body to another; a metastatic tumor contains cells like those in the original (primary) tumor and have spread.
    Clinical implicationMetastatic uveal melanoma is an included indication for Kimmtrak when HLA-A*02:01 positive and ECOG 0-1.
    Policy Summary
    PayerAnthem
    PolicyKimmtrak (tebentafusp-tebn)
    Policy CodePolicy CC-0211
    Change TypeNo material changes
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review DateFeb 20, 2026
    Key ActionObtain prior authorization and document HLA-A*02:01 positivity, diagnosis of unresectable or metastatic uveal melanoma, and ECOG 0-1.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaCodingProvider Actions & RequirementsSite of CareStep TherapyBackgroundDefinitions

    Required Documentation

    Documentation must support: diagnosis of unresectable or metastatic uveal melanoma; positive HLA-A*02:01 genotype; ECOG performance status 0-1; and patient age consistent with policy criteria.

    • Include pathology/imaging or clinical notes confirming unresectable or metastatic uveal melanoma
    • Laboratory/genetic report confirming HLA-A*02:01 positivity
    • Clinical notes documenting ECOG performance status (0-1)
    • Documentation of patient age
    Denial Risk

    Denial Triggers

    Requests may be denied when required criteria or documentation are missing or do not meet the policy (e.g., diagnosis not unresectable/metastatic uveal melanoma; HLA-A*02:01 negative or unknown; ECOG >1; age outside criteria).

    DocumentationMedical records should show evidence of metastatic disease to support coverage determination.
    inv-13: Unresectable — definition
    DefinitionUnable to be removed with surgery.
    Clinical implicationUnresectable uveal melanoma is an included indication for Kimmtrak when HLA-A*02:01 positive and ECOG 0-1.
    DocumentationRecords should indicate that the tumor is not surgically resectable to meet policy criteria.